Citius Pharmaceuticals (Citius Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Apr. 30, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Citius Pharmaceuticals Forward Dividend Yield %?

As of today (2024-04-30), the Forward Annual Dividend Yield of Citius Pharmaceuticals is 0.00%.

As of today (2024-04-30), the Trailing Annual Dividend Yield of Citius Pharmaceuticals is 0.00%.

CTXR's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.45
* Ranked among companies with meaningful Forward Dividend Yield % only.

Citius Pharmaceuticals's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Citius Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, Citius Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Citius Pharmaceuticals's Forward Dividend Yield % falls into.

Citius Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Citius Pharmaceuticals (NAS:CTXR) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Citius Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Pharmaceuticals (Citius Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (NAS:CTXR) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

47N:Germany

Address

11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016

Website

http://www.citiuspharma.com

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Executives

Myron Z Holubiak	director, officer: Vice Chairman	C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Dennis M Mcgrath	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Leonard L Mazur	director, 10 percent owner, officer: Chief Executive Officer	C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Suren G Dutia	director	C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Carol Webb	director	11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
Eugene Myron Holuka	director	11 COMMERCE DRIVE, 11TH FLOOR, CRANFORD NJ 07016
Jaime Bartushak	officer: Chief Financial Officer	C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Myron Czuczman	officer: Chief Medical Officer	C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Howard Safir	director	11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
William Kane	director	11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016